Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries

Authors

  • Pia Baumann Division of Oncology and Hospital Physics, Radiumhemmet Karolinska University Hospital, Sweden
  • Jan Nyman Department of Oncology and Radiation Physics, Sahlgrenska University Hospital Gothenburg, Sweden
  • Ingmar Lax Division of Oncology and Hospital Physics, Radiumhemmet Karolinska University Hospital, Sweden
  • Signe Friesland Division of Oncology and Hospital Physics, Radiumhemmet Karolinska University Hospital, Sweden
  • Morten Hoyer Division of Oncology and Medical Physics, Aarhus University Hospital, Denmark
  • Suzanne Rehn Ericsson Department of Oncology and Radiology, University Hospital, Uppsala, Sweden
  • Karl-Axel Johansson Department of Oncology and Radiation Physics, Sahlgrenska University Hospital Gothenburg, Sweden
  • Lars Ekberg Division of Oncology and Hospital Physics, Malmö University Hospital, Sweden
  • Elisabet Morhed Department of Oncology and Radiology, University Hospital, Uppsala, Sweden
  • Merete Paludan Division of Oncology and Medical Physics, Aarhus University Hospital, Denmark
  • Lena Wittgren Division of Oncology and Hospital Physics, Malmö University Hospital, Sweden
  • Henrik Blomgren Division of Oncology and Hospital Physics, Radiumhemmet Karolinska University Hospital, Sweden
  • Rolf Lewensohn Division of Oncology and Hospital Physics, Radiumhemmet Karolinska University Hospital, Sweden

DOI:

https://doi.org/10.1080/02841860600904862

Abstract

We reviewed results of SBRT treatment of 138 patients with medically inoperable stage I NSCLC treated during 1996–2003 at five different centres in Sweden and Denmark. Mean age was 74 years (range 56–90) with 69 men and 72 women. SBRT was delivered using a 3D conformal multifield technique and a stereotactic body frame. Doses delivered were 30–48 Gy (65% isodose at the periphery of planning target volume, PTV) in 2–4 fractions. Equivalent dose in 2 Gy fractions (EQD2) was in the range of 50–100 Gy. Mean gross tumour volume (GTV) was 39 cm3 (2–436), and planning target volume was 101 cm3 (11–719). Overall response rate (CR, PR) was 61% (84/138). SD was noted in 36% (50/138). During a median follow-up period of 33 months (1–107), 16 (12%) local failures occurred, ten of which also included distant metastases. Local failure was associated with tumour size, target definition and central or pleura proximity. Distant metastases occurred in 25% (35/138) of the patients. Ninety-one (65%) patients died during follow-up of which 55 patients (60%) died of other causes than lung cancer. 

Downloads

Download data is not yet available.

Downloads

Published

2006-01-01

How to Cite

Baumann, P., Nyman, J., Lax, I., Friesland, S., Hoyer, M., Rehn Ericsson, S., … Lewensohn, R. (2006). Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncologica, 45(7), 787–795. https://doi.org/10.1080/02841860600904862